Abstract
The objective of this work is to investigate the occurrence of atherosclerosis and metabolic syndrome (MetS) in ankylosing spondylitis (AS) patients (pts). Twenty-four consecutive AS pts (men, 87.5%; median age, 50.5 years; median disease duration, 16.5 years), fulfilling the modified 1984 New York criteria for AS criteria, and 19 age- and sex-matched controls were investigated. Clinical atherosclerosis was evaluated by physical examination for cardiovascular (CV) diseases and history or drug use for CV events. Subclinical atherosclerosis was detected by mean intima media thickness (a-IMT) and maximum IMT (max-IMT) of carotid arteries using ultrasonography. Laboratory investigations including fasting plasma glucose, total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides were assessed by standard methods, while homocysteine was assessed by chemiluminescence. MetS was assessed using the updated NCEP-ATP III criteria. Disease activity was defined according to the International Ankylosing Spondylitis Assessment Study criteria. The 10-year CV risk (%) profile was evaluated in agreement to the Progetto Cuore criteria. No major CV event was detected in the study population. No significant differences were found when AS pts and controls were compared according to the mean a-IMT (0.52±0.26 vs 0.51±0.13 mm), max-IMT (0.92±0.20 vs 0.85±0.39 mm), prevalence of abnormal max-IMT >1 mm (27.2 vs 5.3%), and 10-year CV risk (9.9±9.6 vs 3.6±1.8%). Systolic blood pressure (p=0.04), triglyceride to HDL cholesterol ratio (p=0.002), and LDL cholesterol (p=0.03) were found significantly higher in AS pts than in controls; on the contrary, HDL cholesterol was pointed out as significantly lower (p<0.001). MetS was found in 11/24 (45.8%) AS pts and in 2/19 (10.5%) controls (p=0.019). No significant relationship emerged in MetS prevalence among AS pts regarding the mean value of age, disease duration, Bath Ankylosing Spondylitis Functional Index, Bath Ankylosing Spondylitis Disease Activity Index, and the Italian version of Health Assessment Questionnaire. This preliminary report points out a higher prevalence of MetS in AS pts than in controls. Further studies are needed to confirm this finding.
Similar content being viewed by others
References
Van Der Linden S, Van Der Hejde D, Braun J (2005) Ankylosing spondylitis. In: Harris ED, Budd RC, Firestein GS, Genovese MC, Sargent JS, Ruddy S, Sledge CB (eds) Kelly’s textbook of rheumatology, 7th edn. Saunders, Philadelphia, PA, pp 1125–1141
Kaprove RE, Little AH, Graham DC, Rosen PS (1980) Ankylosing spondylitis survival in men with and without radiotherapy. Arthritis Rheum 23:57–61
Smith PG, Doll R (1982) Mortality among patients with ankylosing spondylitis after single treatment course with X-rays. BMJ 13:449–460
Lehtinen K (1993) Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis. Ann Rheum Dis 52:174–176
O’Neill TW, Bresnihan B (1992) The heart in ankylosing spondylitis. Ann Rheum Dis 51:705–706
O’Neill TW, King G, Graham IM, Molony J, Bresnihan B (1992) Echocardiographic abnormalities in ankylosing spondylitis. Ann Rheum Dis 51:652–654
Peters MJ, van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT (2004) Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 34:585–592
Sari I, Okan T, Akan S, Cece H, Altay C, Secil M et al (2006) Impaired endothelial function in patients with ankylosing spondylitis. Rheumatology 45:283–286
Kahn R, Buse J, Ferrannini E, Stern M (2005) The metabolic syndrome: time for a critical appraisal. Diabetes Care 28:2289–2304
Rutter MK, Meigs JB, Sullivan LM, D’Agostino RB Sr, Wilson PW (2004) C-reactive protein, the metabolic syndrome and prediction of cardiovascular events in the Framingham Offsprings Study. Circulation 110:380–385
Ridker MK, Wilson PW, Grundy SM (2004) Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 109:2818–2825
Van Der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 27:361–368
Dougados M, Van Der Linden S, Juhlin R, Huitfeldt T, Amor B, Calin A et al (1991) The European Spondyloarthropathy Study Group preliminary criteria for the classification of spondyloarthropathy. Arthritis Rheum 34:1218–1227
Bond MG, Barnes RW, Wiley WA, Wilmoth SK, Chambless LE, Howard G et al (1991) High-resolution B-mode ultrasound reading methods in the Atherosclerosis Risk in Communities (ARIC) cohort. The ARIC Study Group. J Neuroimaging 1:68–73
Howard G, Sharrett R, Heiss G, Evans GW, Chambless LE, Riley WA et al (1993) Carotid artery intima-media thickness distribution in general populations as evaluated by B-mode ultrasound. Stroke 24:297–304
Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 18:499–502
Giampaoli S, Palmieri L, Chiodini P, Ferrario M, Panico S, Pilotto L et al (2004) La carta del rischio cardiovascolare globale. Ital Heart J 5(Suppl 3):177–185
Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA et al (2005) Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. Circulation 112:e285–e290
Braun J, Pharm T, Sieper J, Davis J, Van Der Linden SJ, Dougados M et al (2003) International ASAS consensus statement for the use of anti-tumor necrosis agents in patients with ankylosing spondylitis. Ann Rheum Dis 62:817–824
Calin A, Garrett S, Whitelock H, Kennedy LG, O’Hea J, Malorie P et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21:2281–2285
Ranza R, Marchesoni A, Calori G, Bianchi G, Braga M, Canazza S et al (1993) The Italian version of the functional disability index of the health assessment questionnaire. A reliable instrument for multicenter studies on rheumatoid arthritis. Clin Exp Rheumatol 11:123–128
Dessein PH, Stanwix AE, Joffe BI (2002) Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis. Arthritis Res 4:R5
Magadmi ME, Ahmad Y, Turkie W, Yates AP, Sheikh N, Bernstein RM et al (2006) Hyperinsulinemia, insulin resistance, and circulating oxidized low density lipoprotein in women with systemic lupus erythematosus. J Rheumatol 33:50–56
Doran MF, Brophy S, Mackay K, Taylor G, Calin A (2003) Prediction of long term outcome in ankylosing spondylitis. J Rheumatol 30:316–320
Divecha H, Sattar N, Rumley A, Cherry L, Loe GD, Sturrock R (2005) Cardiovascular risk parameters in men with ankylosing spondylitis in comparison with non-inflammatory control subjects: relevance of systemic inflammation. Clin Sci (Lond) 109:171–176
Joven J, Rubies-Prat J, Ras MR, de la Figuera M, Lience E, Masdeu S (1984) High density lipoproteins cholesterol subfractions and apoprotein A-I in patients with rheumatoid arthritis and ankylosing spondylitis. Arthritis Rheum 27:1199–2000
Alves MG, Espirito-Santo J, Queiroz MV, Madeira H, Maciera-Coelho E (1988) Cardiac alterations in ankylosing spondylitis. Angiology 39:67–571
Magi L, Stramenga C, Morosini P (2005) Prevalence of the metabolic syndrome among Italian adults. Findings from the SIMAP study. Recenti Prog Med 96:280–283
Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K (2004) Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in non diabetic European men and women. Arch Intern Med 164:1066–1076
Malik S, Wong ND, Franklin SS, Kamath TV, L’italein GJ, Pio JR et al (2004) Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 110:1245–1250
Lorenzo C, Okoloise M, Williams K, Stern MP, Hafner SM (2003) The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. Diabetes Care 26:3153–3156
Dessein PH, Joffe BI, Stanwix A, Botha AS, Moomal Z (2002) The acute phase response does not fully predict the presence of insulin resistance and dyslipidemia in inflammatory arthritis. J Rheumatol 29:462–466
Dessein PH, Joffe BI, Stanwix AE (2005) Should we evaluate insulin sensitivity in the rheumatoid arthritis? Semin Arthritis Rheum 35:5–7
Stamler J, Stamler R, Neaton JD (1993) Blood pressure, systolic and diastolic and cardiovascular risks. U.S. population data. Arch Intern Med 153:598–615
Kannel WB, Larson M (1993) Long-term epidemiologic prediction of coronary disease. The Framingham experience. Cardiology 82:137–152
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Malesci, D., Niglio, A., Mennillo, G.A. et al. High prevalence of metabolic syndrome in patients with ankylosing spondylitis. Clin Rheumatol 26, 710–714 (2007). https://doi.org/10.1007/s10067-006-0380-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-006-0380-5